Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome Before and After Metformin Therapy
Polycystic ovarian syndrome affects 5–10% of women; it represents the most common cause of hyperinsulinemia with anovulation. Many biomarkers are used to assess insulin resistance. Irisin is a newly discovered myokine associated with insulin resistance and other metabolic syndromes.
To measure the serum level of irisin in polycystic ovary syndrome patients and assess the effect of metformin treatment on its level.
This study was a prospective interventional study conducted in a private clinic and Al-Yarmouk Teaching Hospital in Baghdad City from January 1, 2017, till April 1, 2018. A hundred women were enrolled in the study. Fifty of them suffered from PCOS and other fifty were normal. They were randomly selected according to computer-based randomization and assigned as a control group. Hormonal, biochemical and oral glucose tolerance tests were performed on all patients, including Irisin. The results have been compared for both groups. Twenty-nine women of PCOS patients received metformin for a course period of 4 months as the changes in their biochemical results were evaluated.
Serum irisin level was higher in patients group compared to control group (312 ± 134.3 and 188.4 ± 53.8 μg/l, respectively), and the difference was statistically significant as the p value < 0.001. After 4 months treatment with metformin for twenty-nine polycystic patients, there was a significant reduction in irisin level by (165.8 ± 55.6 μg/l) and the p value was significant.
Irisin might be used as a simple test for the prediction of insulin resistance in PCOS patients.
KeywordsPolycystic ovary syndrome Hyperinsulinemia Irisin and myokine
Funding was provided by Fatin Shallal (Grant No. 07901761136).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
This manuscript has not been submitted anywhere before, and it was approved by all authors to be submitted in this journal. The protocol of the study has been approved by the Scientific Researches Committee in Obstetrics and Gynecology at Al-Yarmouk Hospital. Informed consent has been taken from all participants who were 100 Iraqi women enrolled in this study.
- 10.Katarzyna P, Łukasz Ł, Katarzyna K, et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. J Gynecol Endocrinol 2015;31(11):907–11.Google Scholar
- 15.Benedini S, Dozio E, Invernizzi PL, et al. Irisin: a potential link between physical exercise and metabolism: an observational study in differently trained subjects, from elite athletes to sedentary people. J Diabetes Res. 2017. https://doi.org/10.1155/2017/1039161.CrossRefPubMedPubMedCentralGoogle Scholar